Actionnariat et activité des initiés pour GT Biopharma, Inc. (GTBP): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $7.81 |
| Capitalisation | $10M |
| Bourse | NASDAQ |
| Pays | US |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $19000 | $576000 | $60000 | $28000 | $5.3M | $9.0M | $5.7M | $1.1M | $4.0M | $6.8M |
| Placements à Court Terme | 0 | 0 | 0 | 0 | 0 | $23.0M | $10.8M | $12.9M | 0 | 0 |
| Créances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stocks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Courants | $21000 | $576000 | $90000 | $274000 | $5.7M | $32.2M | $16.6M | $14.1M | $4.2M | $8.1M |
| Immobilisations Corporelles | $4000 | $6000 | $35000 | $110000 | 0 | 0 | $165000 | $53000 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Incorporels | 0 | $253.8M | $25.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Totaux | $25000 | $254.4M | $25.4M | $396000 | $5.7M | $32.2M | $16.7M | $14.1M | $4.2M | $8.1M |
| Dettes Fournisseurs | $2.1M | $2.5M | $1.8M | $1.9M | $2.2M | $8.2M | $3.1M | $4.3M | $3.9M | $748000 |
| Dette à Court Terme | $12.4M | $31000 | $10.8M | $13.2M | $26.3M | $31000 | 0 | 0 | 0 | 0 |
| Passifs Courants | $18.9M | $2.7M | $14.0M | $19.7M | $35.1M | $10.3M | $4.9M | $6.6M | $5.9M | $2.3M |
| Dette à Long Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Passifs Totaux | $18.9M | $2.7M | $14.0M | $19.7M | $35.1M | $10.3M | $5.0M | $6.6M | $5.9M | $2.3M |
| Réserves | -$124.6M | -$269.5M | -$528.7M | -$567.3M | -$595.6M | -$653.6M | -$674.5M | -$682.1M | -$695.2M | -$723.9M |
| Capitaux Propres | -$18.8M | $251.9M | $11.5M | -$19.1M | -$29.3M | $21.9M | $11.7M | $7.5M | -$1.7M | $5.8M |
| Dette Totale | $12.4M | $31000 | $10.8M | $13.4M | $26.3M | $31000 | $174000 | $58000 | 0 | 0 |
| Dette Nette | $12.4M | -$545000 | $10.7M | $13.3M | $21.0M | -$31.9M | -$16.3M | -$13.9M | -$4.0M | -$6.8M |
| Fonds de Roulement | -$18.9M | -$2.1M | -$13.9M | -$19.4M | -$29.4M | $21.9M | $11.6M | $7.4M | -$1.7M | $5.8M |
Santé financière
| Dette / Capitaux propres | 0.00 |
| Ratio de liquidité | 2.61 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -128.11 |
Rentabilité
| Rentabilité des capitaux propres | -443.08% |
| Rentabilité du capital investi | -457.75% |
| Rentabilité des actifs | -381.53% |
| Marge brute | 0.00% |
| Marge opérationnelle | 0.00% |
| Marge nette | 0.00% |
Entreprises liées: ARTL · CARM · DRMA · LIPO · PBM · PTIX · REVB
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de GTBP: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions